Tirzepatide's commercial name in the UK — what Mounjaro is and why it matters

Step 1, understanding why a medicine has both a generic name and a commercial one

Every licensed medicine has two names running in parallel. The generic name (tirzepatide) is the international non-proprietary name assigned to the active molecule. The commercial name (Mounjaro) is the brand Eli Lilly registered with the MHRA when seeking UK marketing authorisation. Both names refer to the same compound; they simply operate in different contexts.

When a prescriber writes a prescription, they may use either name. When a pharmacist dispenses and when a patient receives the box, they will see Mounjaro. The relationship between the tirzepatide brand name and the generic follows the same pattern as, say, ibuprofen versus Nurofen, but because tirzepatide is still under patent, only Eli Lilly's version is currently available. There is no generic tirzepatide on the UK market, so the names are, in practical terms, interchangeable right now.

Knowing this protects you as a patient. If a seller offers you "tirzepatide" packaged in anything other than an authentic Mounjaro KwikPen box, that is a serious red flag. The MHRA has warned publicly about counterfeit weight-loss pens sold online, including fake tirzepatide pens seized in a 2025 raid, roughly 20 million doses of illegally traded weight-loss medicines (worth around £45 million) were intercepted by enforcement teams. Genuine supply always arrives in branded, tamper-evident Eli Lilly packaging.

Step 2 (confirming you are looking at the correct UK product

A quick, practical check takes under a minute: go to the MHRA's Drug Safety Update index on GOV.UK and search "tirzepatide") every communication you find will reference it as Mounjaro. That match confirms you are reading about the right product for the UK market.

People arriving from US sources sometimes encounter the name Zepbound. That is the American brand name for tirzepatide in the weight-management indication, approved by the FDA. It does not exist as a UK product. No UK pharmacy can legally supply Zepbound; the medicine available here is Mounjaro, under an MHRA licence. Similarly, searching for tirzepatide under European trade names leads nowhere useful for a UK patient, the MHRA operates separately from the EMA since 2021.

The full picture of tirzepatide names across markets is covered in detail on a dedicated page, but the short version is straightforward: UK equals Mounjaro, full stop.

Step 3, what the Mounjaro licence actually covers

Knowing the commercial name also tells you what the medicine is licensed to do. The NHS patient-level guidance for tirzepatide confirms that Mounjaro is licensed in the UK for two purposes: weight management in adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol), and the management of type 2 diabetes. Those two indications share a product name but are governed by different prescribing contexts.

For weight management, NICE appraised tirzepatide (Mounjaro) in technology appraisal TA1026, published December 2024, recommending it within specific NHS criteria. Private prescriptions follow the SmPC's licensed criteria directly. Either way, the prescriber is assessing you against the indications attached to the Mounjaro licence, which is why the commercial name, the ingredient name and the clinical criteria all connect.

If you are comparing Mounjaro with other options, the cost context for Mounjaro in the UK is worth reading before making any decisions. And if you want to understand how this medicine is actually supplied through a regulated pharmacy, our Mounjaro overview covers the full picture.

Step 4, why none of this is just a branding exercise

Some readers wonder whether the distinction between "tirzepatide" and "Mounjaro" is purely marketing. It is not, for one practical reason: a prescription-only medicine can only be dispensed when there is a valid prescription for a licensed product. The prescriber writes the product's name (or the INN), the pharmacy verifies it against their licensed stock, and the MHRA tracks the product through the supply chain using its registered name. That chain of accountability depends on the commercial name being consistent and verifiable.

For patients, the takeaway is simple. If you are researching this treatment, searching for either "tirzepatide" or "Mounjaro" in a UK context will lead you to the same medicine. The tirzepatide name and brand page explores this in more depth. What never changes is the requirement for a prescription: a clinician reviews your health information before any supply is made, regardless of which name you used to find the medicine.

Our prescribers are available through a free consultation if you want to discuss whether Mounjaro is clinically suitable for you. There is no obligation, and the review is conducted by a GPhC-registered Independent Prescriber, a real clinician reading your answers, the same day you submit them. Speak to our prescribers to get started.